Evidence map›Paper›PMID 38345212›Full record

ArticleJournal of addiction medicine

Mapping Buprenorphine Access at Philadelphia Pharmacies.

Shoshana V Aronowitz, Rachel French, Allison Schachter, Emily Seeburger, Nicole O'Donnell, Jeanmarie Perrone, Margaret Lowenstein

Abstract read
In one paragraph

Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shoshana V AronowitzFrom the University of Pennsylvania School of Nursing, Philadelphia, PA (SA); University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (RF, AS, ES, NO, JP, ML); University of Pennsylvania Center for Emergency Care Policy and Research, Philadelphia, PA (ES); University of Pennsylvania Urban Health Lab, Philadelphia, PA (SA, ES); and University of Pennsylvania Center for Addiction Medicine and Policy, Philadelphia, PA (SA, RF, NO, JP, ML).
Rachel French
Allison Schachter
Emily Seeburger
Nicole O'Donnell
Jeanmarie Perrone
Margaret Lowenstein

Funding

Improving transitions of care for hospitalized patients with opioid use disorderK23DA055087 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI Margaret Lowenstein · 2022 to 2026
$959k
Improving access to opioid use disorder treatment among marginalized patients with a tailored telehealth interventionK23DA057528 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI Shoshana V. Aronowitz · 2023 to 2026
$855k
NIDA NIH HHS K23 DA055087NIDA NIH HHS K23 DA057528
6 · The paper itself

Abstract

objectivesBuprenorphine is not reliably stocked in many pharmacies, and pharmacy-level barriers may deter patients from opioid use disorder care. We surveyed all outpatient pharmacies in Philadelphia to describe variation in buprenorphine access and developed a map application to aid in identifying pharmacies that stock the medication.

methodsUsing a dataset from the Bureau of Professional and Occupational Affairs, we conducted a telephone survey of operating outpatient pharmacies (N = 422) about their buprenorphine stocking and dispensing practices. We used ArcGIS Pro 3.0.3 to join US Census Bureau ZIP code-level race and ethnicity data, conduct descriptive analyses, and create a map application.

resultsWe collected data from 351 pharmacies (83% response rate). Two hundred thirty-eight pharmacies (68%) indicated that they regularly stock buprenorphine; 6 (2%) would order it when a prescription is sent. Ninety-one (26%) said that they do not stock or order buprenorphine, and 16 (5%) were unsure. We identified 137 "easier access" pharmacies (39%), meaning they regularly stock buprenorphine, dispense to new patients, and have no dosage maximums. Zip codes with predominantly White residents had a median (interquartile range) of 3 (2-4) "easier access" pharmacies, and those with predominantly Black residents a median (interquartile range) of 2 (1-4.5). Nine zip codes had no "easier access" pharmacies, and 3 had only one; these 3 zip codes are areas with predominantly Black residents.

conclusionsBuprenorphine access is not equitable across Philadelphia and a quarter of pharmacies choose not to carry the medication. Our map application may be used to identify pharmacies in Philadelphia that stock buprenorphine.

Indexed as

BuprenorphineHealth Services AccessibilityOpioid-Related DisordersHumansNarcotic AntagonistsOpiate Substitution TreatmentPharmaciesPhiladelphiaBuprenorphineNarcotic Antagonists

Identifiers

PMID38345212
PMCPMC11150095

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.